Pharvaris (PHVS) News Today → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free PHVS Stock Alerts $20.35 -1.36 (-6.26%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | globenewswire.comPharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesMay 13, 2024 | americanbankingnews.comWedbush Analysts Reduce Earnings Estimates for Pharvaris (NASDAQ:PHVS)May 13, 2024 | americanbankingnews.comPharvaris (NASDAQ:PHVS) Given New $31.00 Price Target at WedbushMay 13, 2024 | americanbankingnews.comQ2 2024 Earnings Forecast for Pharvaris Issued By Leerink Partnrs (NASDAQ:PHVS)May 10, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | markets.businessinsider.comPharvaris’s Promising Drug Candidate Deucrictibant Bolsters Buy RatingMay 9, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Pharvaris (PHVS)May 9, 2024 | msn.comPHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024May 8, 2024 | globenewswire.comPharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 22, 2024 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Up 8%Pharvaris (NASDAQ:PHVS) Stock Price Up 8%April 22, 2024 | marketbeat.comMorgan Stanley Reiterates "Overweight" Rating for Pharvaris (NASDAQ:PHVS)Morgan Stanley reaffirmed an "overweight" rating and issued a $34.00 target price on shares of Pharvaris in a report on Monday.April 15, 2024 | markets.businessinsider.comPharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE TreatmentApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid FinancialsApril 12, 2024 | finance.yahoo.comPharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth PlansApril 12, 2024 | investing.comPharvaris appoints new CFO to bolster financial strategyApril 11, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial StabilityApril 11, 2024 | seekingalpha.comPHVS Pharvaris N.V.April 10, 2024 | investorplace.comPHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023April 10, 2024 | globenewswire.comPharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 10, 2024 | globenewswire.comPharvaris Appoints David Nassif, J.D., as Chief Financial OfficerApril 4, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceApril 3, 2024 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Down to $22.15Pharvaris (NASDAQ:PHVS) Shares Gap Down to $22.15March 18, 2024 | globenewswire.comPharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesMarch 6, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesMarch 5, 2024 | globenewswire.comPharvaris to Participate in the Leerink Global Biopharma Conference 2024February 29, 2024 | marketbeat.comPharvaris (NASDAQ:PHVS) Short Interest Down 49.0% in FebruaryPharvaris (NASDAQ:PHVS - Get Free Report) was the recipient of a large decrease in short interest in February. As of February 15th, there was short interest totalling 108,300 shares, a decrease of 49.0% from the January 31st total of 212,300 shares. Based on an average daily volume of 162,600 shares, the short-interest ratio is presently 0.7 days. Currently, 1.1% of the shares of the company are short sold.February 26, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE TreatmentFebruary 25, 2024 | msn.comPharvaris N.V. (PHVS) Price Target Increased by 6.19% to 34.97February 22, 2024 | finance.yahoo.comPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingFebruary 22, 2024 | globenewswire.comPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingFebruary 16, 2024 | finance.yahoo.comPharvaris Announces Extraordinary Meeting of ShareholdersFebruary 16, 2024 | globenewswire.comPharvaris Announces Extraordinary Meeting of ShareholdersFebruary 14, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)January 26, 2024 | finance.yahoo.comPharvaris to Present at the WSAAI Annual Meeting 2024January 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris with Increased Price Target Following FDA Regulatory AdvancesJanuary 23, 2024 | finance.yahoo.comPharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE ProgramJanuary 22, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksJanuary 22, 2024 | msn.comPharvaris rises as FDA lifts hold on hereditary angioedema candidateJanuary 22, 2024 | markets.businessinsider.comPharvaris Says FDA Lifts Clinical Hold On IND For Deucrictibant For Treatment Of HAE AttacksJanuary 22, 2024 | finance.yahoo.comPharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksJanuary 17, 2024 | seekingalpha.comPharvaris: Digging Deep For Sufficient Market SizeJanuary 9, 2024 | markets.businessinsider.comPositive Clinical Trials and Strong Financial Position Support Buy Rating for PharvarisJanuary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris Amid Anticipated Clinical Updates and Positive Trial ProspectsJanuary 5, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesJanuary 5, 2024 | finance.yahoo.comPharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesDecember 17, 2023 | msn.comPharvaris (PHVS) Price Target Increased by 38.65% to 32.93December 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Pharvaris (PHVS) and Tourmaline Bio (TRML)December 11, 2023 | finance.yahoo.comPharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms who were rewarded as market cap surged US$578m last weekDecember 8, 2023 | tmcnet.comPharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Free report reveals “two-baggers” for 2024 (Ad)We’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable. Download your free report today! PHVS Media Mentions By Week PHVS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHVS News Sentiment▼-0.600.42▲Average Medical News Sentiment PHVS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHVS Articles This Week▼102▲PHVS Articles Average Week Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Grifols News LAVA Therapeutics News Mainz Biomed News NLS Pharmaceutics News Procaps Group News Qilian International Holding Group News Aclarion News Alpha Tau Medical News Alvotech News American Oncology Network News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHVS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryShocking $16T Elon Musk Crypto LeakCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMost important medical advance in 100 yearsThe Oxford ClubCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMissed NVDA? Buy this AI stock NOWChaikin AnalyticsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
